Equities

Sagimet Biosciences Inc

Sagimet Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.28
  • Today's Change-0.10 / -2.96%
  • Shares traded304.89k
  • 1 Year change-72.32%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Sagimet Biosciences Inc increased its cash reserves by 47,456.33%, or 74.98m. Cash Flow from Financing totalled 86.17m or 4,308.35% of revenues. In addition the company used 23.77m for operations while cash from investing totalled 12.58m.
Cash flow per share-1.14
Price/Cash flow per share--
Book value per share5.74
Tangible book value per share5.74
More ▼

Balance sheet in USDView more

Sagimet Biosciences Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio29.11
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.